Elanco (ELAN) Q2 Revenue Jumps 5%
Elanco Animal Health (NYSE:ELAN), a global animal health company providing products and services for pets and livestock, reported its second quarter 2025 earnings on August 7, 2025. The most notable news was a strong revenue beat and solid performance in its innovation portfolio, especially from new pet and cattle products. GAAP revenue reached $1,241 million, topping the consensus GAAP estimate of $1,186 million. Adjusted earnings per share (EPS) came in at $0.26, ahead of the $0.20 expected by analysts (non-GAAP). Although margins and adjusted EBITDA declined, the quarter reflected accelerating growth, leading management to increase full-year 2025 revenue and adjusted EPS guidance.
Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report.
Elanco Animal Health develops and markets medicines and vaccines for both companion animals (pet dogs and cats) and farm animals (cattle, pigs, poultry, and others). It operates in over 90 countries and maintains a portfolio that spans around 200 brands. The company’s product suite includes treatments that prevent flea and tick infestations, improve animal growth and health, and treat or prevent a range of conditions.
Source Fool.com
